Drug intelligence / Profile preview

TLD-002

Development stage: Unknown
Lead developer: Tilde Sciences

Overview

TLD-002 is an investigational drug candidate being developed by Tilde Sciences for the treatment of rare metabolic disorders. It is the lead candidate within the company's 'Select Metabolism Pipeline.' While the specific molecular target, mechanism of action, and modality have not been publicly disclosed, the drug has progressed to the Proof of Concept stage of clinical development, which typically corresponds to Phase 2. Tilde Sciences focuses on addressing unmet needs in rare diseases, and TLD-002 represents their most advanced internal pipeline asset for metabolic indications.

Beyond the preview

Go deeper on TLD-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLD-002.

Explore the full profile